{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:40:07Z","timestamp":1762004407863},"reference-count":39,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Rifamycins are key sterilizing drugs in the current treatment of active tuberculosis (TB). Daily dosing of rifapentine (P), a potent rifamycin with high intracellular accumulation, in place of rifampin (R) in the standard antitubercular regimen significantly shortens the duration of treatment needed to prevent relapse in a murine model of active TB. We undertook the current study to compare directly the activities of human-equivalent doses of P and R in a guinea pig model of chronic TB, in which bacilli are predominantly extracellular within human-like necrotic granulomas. Hartley strain guinea pigs were aerosol infected with \u223c200 bacilli of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mycobacterium tuberculosis<\/jats:named-content>\n            H37Rv, and treatment given 5 days\/week was initiated 6 weeks later. R at 100 mg\/kg of body weight and P at 100 mg\/kg were given orally alone or in combination with isoniazid (H) at 60 mg\/kg and pyrazinamide (Z) at 300 mg\/kg. Culture-positive relapse was assessed in subgroups of guinea pigs after completion of 1 and 2 months of treatment. Human-equivalent doses of R and P showed equivalent bactericidal activity when used alone and in combination therapy. In guinea pigs treated with rifampin, isoniazid, and pyrazinamide (RHZ) or PHZ, microbiological relapse occurred in the lungs of 8\/10 animals treated for 1 month and in 0\/10 animals treated for 2 months. Substitution of P for R in the standard antitubercular regimen did not shorten the time to cure in this guinea pig model of chronic TB. Data from ongoing clinical trials comparing the activity of these two drugs are awaited to determine the relevance of the guinea pig TB model in preclinical drug screening.\n          <\/jats:p>","DOI":"10.1128\/aac.00500-12","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T02:53:11Z","timestamp":1335840791000},"page":"3726-3731","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["Rifapentine Is Not More Active than Rifampin against Chronic Tuberculosis in Guinea Pigs"],"prefix":"10.1128","volume":"56","author":[{"given":"Noton K.","family":"Dutta","sequence":"first","affiliation":[{"name":"Departments of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"Illei","sequence":"additional","affiliation":[{"name":"Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Florida, Gainesville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Pinn","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khisimuzi E.","family":"Mdluli","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;"},{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques H.","family":"Grosset","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros C.","family":"Karakousis","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;"},{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;"},{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01524-10"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr188"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/605605"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq007"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq277"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000933"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2055"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09742-8"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-905OC"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006297"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00789-09"},{"key":"e_1_3_3_14_2","first-page":"A6413","article-title":"A phase II study of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis: preliminary results for tuberculosis trials consortium study 29","volume":"183","author":"Dorman S","year":"2011","unstructured":"DormanS . 2011. A phase II study of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis: preliminary results for tuberculosis trials consortium study 29. Am. J. Respir. Crit. Care Med. 183:A6413.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.3.548"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm485"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/589515"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00276-07"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/430377"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(00)01901-8"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2073"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01521-09"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2670"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.1.12"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.2353\/ajpath.2009.081075","article-title":"Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts","volume":"174","author":"Pichugin AV","year":"2009","unstructured":"PichuginAV YanBS SloutskyA KobzikL KramnikI. 2009. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am. J. Pathol. 174:2190\u20132201.","journal-title":"Am. J. Pathol."},{"key":"e_1_3_3_28_2","first-page":"83","article-title":"Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts","volume":"42","author":"Rees RJ","year":"1961","unstructured":"ReesRJ HartPD. 1961. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br. J. Exp. Pathol. 42:83\u201388.","journal-title":"Br. J. Exp. Pathol."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200602-280OC"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.200807-1029OC","article-title":"Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?","volume":"178","author":"Rosenthal IM","year":"2008","unstructured":"RosenthalIM ZhangM AlmeidaD GrossetJH NuermbergerEL. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178:989\u2013993.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040344"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05633-11"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00978-10"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1289\/ehp.94102s9101","article-title":"Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies","volume":"102","author":"Strolin BM","year":"1994","unstructured":"StrolinBM DostertP. 1994. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ. Health Perspect. 102:101\u2013105.","journal-title":"Environ. Health Perspect."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-195607000-00006"},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium","volume":"353","author":"Vernon A","year":"1999","unstructured":"VernonA BurmanW BenatorD KhanA BozemanL. 1999. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353:1843\u20131847.","journal-title":"Lancet"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200311-1612OC"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-951OC"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00353-10"},{"key":"e_1_3_3_40_2","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1164\/rccm.201012-1949OC","article-title":"Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice","volume":"183","author":"Zhang M","year":"2011","unstructured":"ZhangM . 2011. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183:1254\u20131261.","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00500-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00500-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:07:36Z","timestamp":1645452456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00500-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1128\/AAC.00500-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00500-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"2012-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}